Devonian Health Group Inc. (TSXV:GSD)
0.2500
0.00 (0.00%)
Mar 28, 2025, 4:00 PM EST
Devonian Health Group Revenue
Devonian Health Group had revenue of 5.85M CAD in the quarter ending October 31, 2024, with 359.79% growth. This brings the company's revenue in the last twelve months to 22.39M, up 598.16% year-over-year. In the fiscal year ending July 31, 2024, Devonian Health Group had annual revenue of 17.82M with 659.60% growth.
Revenue (ttm)
22.39M
Revenue Growth
+598.16%
P/S Ratio
1.65
Revenue / Employee
3.20M
Employees
8
Market Cap
37.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jul 31, 2024 | 17.82M | 15.47M | 659.60% |
Jul 31, 2023 | 2.35M | 40.20K | 1.74% |
Jul 31, 2022 | 2.31M | 830.50K | 56.32% |
Jul 31, 2021 | 1.47M | -668.47K | -31.19% |
Jul 31, 2020 | 2.14M | -1.86M | -46.49% |
Jul 31, 2019 | Pro | Pro | Pro |
Jul 31, 2018 | Pro | Pro | Pro |
Jul 31, 2017 | Pro | Pro | Pro |
Jul 31, 2016 | Pro | Pro | Pro |
Jul 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Green Thumb Industries | 1.64B |
dentalcorp Holdings | 1.55B |
Sienna Senior Living | 893.16M |
WELL Health Technologies | 957.69M |
Extendicare | 1.47B |
Curaleaf Holdings | 1.93B |
Trulieve Cannabis | 1.71B |
Cronos Group | 169.23M |
Devonian Health Group News
- 5 weeks ago - Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis - Financial Post
- 6 weeks ago - Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Financial Post
- 7 weeks ago - Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study - Financial Post